The expression and clinical significance of YAP and cIAP1 in ovarian serous adenocarcinoma

Objective: To investigate the expression and clinical significance of yes-associate protein (YAP) and cellular inhibitor of apoptosis of protein-1 (cIAP1) in ovarian serous adenocarcinoma. Materials and Methods: The expression of YAP and cIAP1 were detected by immunohistochemistry (IHC) in 62 ovarian tumor tissues. The association of YAP, cIAP1, clinical pathological characteristics in patients, and the prognosis were further analyzed. Results: Among 62 ovarian serous adenocarcinoma tissues obtained from the patients, the positive and the strong positive rate of YAP in patients with tumor tissues were significantly higher than normal tissues. Similar results were found for cIAP1. Moreover, YAP expression was correlated to cIAP1 expression. Furthermore, the expression of YAP and cIAP1 was significantly related to the low tumor differentiation, recurrence, and platinum resistance. Uni-variable analysis showed that YAP expression, FIGO Stage, lymphatic metastasis, ascites as initiating symptom, and the platinum resistance were factors affecting progression-free survival (PFS) of patients. On the other hand, the overall survival rate (OS) was affected by YAP and cIAP1 expression, age, FIGO Stage, recurrence, and platinum resistance. The multi-variable analysis demonstrated that resistance to the initial platinum therapy and the expression of YAP were independent prognosis factors that affected the postoperative OS in ovarian serous adenocarcinoma. The co-expression of YAP and cIAP1 were negatively associated with postoperative PFS and OS in ovarian serous adenocarcinoma patients. Conclusion: YAP and cIAP1 may be relevant to the initiation and growth of the ovarian serous adenocarcinoma and they may serve as negative prognosis factor for ovarian serous adenocarcinoma prognosis.

Ovarian serous adenocarcinoma; YAP; cIAP1; Immunohistochemistry

[1] Ledermann J, Raja F, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C., ESMO Guidelines Working Group: “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2013, 24, vi24.

[2] Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A.: “Ovarian cancer”. Lancet, 2014, 384, 1376.

[3] Gloss B.S., Samimi G.: “Epigenetic biomarkers in epithelial ovarian cancer”. Cancer Lett., 2014, 342, 257.

[4] Sudol M.: “Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product”. Oncogene, 1994, 9, 2145.

[5] Huang J., Wu S., Barrera J., Matthews K., . Pan D.: “The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP”. Cell, 2005, 122, 421.

[6] Overholtzer M., Zhang J., Smolen G.A., Muir B., Li W., Sgroi D.C., et al.: “Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon”. Proc. Natl. Acad. Sci. U S A, 2006, 103, 12405.

[7] Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., et al.: “Elucidation of a universal size-control mechanism in Drosophila and mammals”. Cell, 2007, 130, 1120.

[8] Cheng L., Zhou Z., Flesken-Nikitin A., Toshkov I.A., Wang W., Camps J., et al.: “Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency”. Oncogene, 2010, 29, 5700.

[9] Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al.: “Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach”. Cell, 2006, 125, 1253.

[10] Steinhardt A.A., Gayyed M.F., Klein A.P., Dong J., Maitra A., Pan D., et al.: “Expression of Yes-associated protein in common solid tumors”. Hum. Pathol., 2008, 39, 1582.

[11] Hall C.A., Wang R., Miao J., Oliva E., Shen X., Wheeler T., et al.: “Hippo pathway effector Yap is an ovarian cancer oncogene”. Cancer Res., 2010, 70, 8517.

[12] Xia Y., Zhang Y-L., Yu C., Chang T., Fan H-Y.: “YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian can- cer initiated cells”. PloS One, 2014, 9, e109575.

[13] Psyrri A., Yu Z., Bamias A., Weinberger P.M., Markakis S., Kowalski D., Camp R.L., et al.: “Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1179.

[14] Gill C., Dowling C., O’Neill A.J., Watson R.W.G.: “Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation”. Mol. Cancer, 2009, 8, 1.

[15] Basu S., Totty N.F., Irwin M.S., Sudol M., Downward J.: “Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis”. Mol. Cell, 2003, 11, 11.

[16] Shakibaei M., Harikumar K.B., Aggarwal B.B.: “Resveratrol addiction: to die or not to die”. Mol. Nutr. Food Res., 2009, 53, 115.